Together with other PPARγ agonists, they are used or are under studies for the treatment of oxidative stress-related diseases such as diabetes, vascular diseases [33–35], Parkinson's [36], Alzheimer's [37], nonalcoholic steatohepatitis (NASH) [38], and Huntington's [39]. This evidence concerns the gene PPARG and diabetes mellitus.